PALI insider trading
HealthcarePALISADE BIO, INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About PALISADE BIO, INC.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Company website: www.palisadebio.com
PALI insider activity at a glance
FilingIQ has scored 106 insider transactions for PALI since Apr 27, 2021. The most recent filing in our index is dated Jun 10, 2026.
Across the full history, 26 open-market purchases
and 3 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PALI insider trades is 64.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PALI Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PALI?
- FilingIQ tracks 106 Form 4 insider transactions for PALI (PALISADE BIO, INC.), covering filings from Apr 27, 2021 onwards. 1 of those were filed in the last 90 days.
- Are PALI insiders net buyers or net sellers?
- Across the full Form 4 history for PALI, 26 transactions (25%) were open-market purchases and 3 (3%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PALI insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is PALI in?
- PALISADE BIO, INC. (PALI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $258.12M.
Methodology & sources
Every PALI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.